FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 342:887-888 March 23, 2000 Number 12 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Lai, H.-C. PubMed Citation

In patients with cystic fibrosis, the inflammatory response in the airways to bacterial infection is excessive and deleterious. Thus, interrupting the inflammatory response is a goal of therapy. In a clinical trial of prednisone, given on alternate days at a dose of either 1 or 2 mg per kilogram of body weight to patients 6 to 14 years of age who had cystic fibrosis and mild-to-moderate lung disease, pulmonary function was significantly better in the group that received 1 mg of prednisone per kilogram than in the placebo group.¹ However, prednisone treatment also caused diabetes, cataracts, and growth retardation at . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Gibson, R. L., Burns, J. L., Ramsey, B. W. (2003). Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis. Am. J. Respir. Crit. Care Med. 168: 918-951 [Abstract] [Full Text]  
• Wohl, M. E. B., Majzoub, J. A. (2000). Asthma, Steroids, and Growth. NEJM 343: 1113-1114 [Full Text]